GFM
LXEO icon

GF Fund Management’s Lexeo Therapeutics LXEO Stock Holding History

GF Fund Management’s Portfolio LXEO Stock Details LXEO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$7.19K Sell
1,545
-83
-5% -$449 ﹤0.01% 555
2026
Q1 		$9.35K Buy
1,628
+194
+14% +$1.38K ﹤0.01% 563
2025
Q4 		$14.2K Buy
1,434
+272
+23% +$2.48K ﹤0.01% 546
2025
Q3 		$7.72K Buy
1,162
+342
+42% +$1.65K ﹤0.01% 574
2025
Q2 		$3.3K Hold
820
– – ﹤0.01% 640
2025
Q1 		$2.85K Buy
820
+126
+18% +$558 ﹤0.01% 643
2024
Q4 		$4.57K Buy
+694
New +$5.47K ﹤0.01% 613

Other funds holding LXEO

SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $2.21B AUM 431.26% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return

GF Fund Management's LXEO Position: Q2 2026 in Review

GF Fund Management reduced its Lexeo Therapeutics (LXEO) stake by 5.1% in Q2 2026, selling an estimated $449 and leaving 1,545 shares worth $7.19K. The position accounts for ﹤0.01% of the portfolio, ranked #555.

GF Fund Management first reported a position in LXEO in Q4 2024 and has held it in 7 quarters since. The position peaked at $14.2K in Q4 2025. 142 funds tracked by Wall St. Rank hold LXEO as of Q2 2026.

  • GF Fund Management held 1,545 shares of Lexeo Therapeutics worth $7.19K as of Q2 2026.
  • GF Fund Management sold 83 Lexeo Therapeutics shares in Q2 2026, an estimated $449.
  • Lexeo Therapeutics made up ﹤0.01% of GF Fund Management's portfolio in Q2 2026, its #555 holding.
  • GF Fund Management first reported a position in Lexeo Therapeutics in Q4 2024 and has held it in 7 quarters since.
  • GF Fund Management's Lexeo Therapeutics position peaked at $14.2K in Q4 2025.
  • 142 funds tracked by Wall St. Rank held Lexeo Therapeutics as of Q2 2026.

Based on GF Fund Management's 13F filing for Q2 2026, filed 7 Aug 2026.